European Commission favours MRNA technology when purchasing new vaccines

The European Commission intends to focus on vaccines using the so-called MRNA technique in future orders for corona vaccines, such as PFIZER/Biontech and Moderna. That is what President Ursula von der Leyen said.

This intention does not mean that pharmaceuticals who do not use this technique do not have a chance in a new procurement round. Von der Leyen also said that the committee has a preference for vaccines produced in Europe.

The European Commission intends to order 1.8 billion doses of vaccine for new vaccination rounds for the period 2021-2023. The German pharmaceutical company Curevac is also working on a vaccine made using the MRNA technique. It is expected that this vaccine will be available in the coming summer.

In vaccines using MRNA technique, a person‘s body creates a protein of the virus on the basis of genetic material, against which the body will produce antibodies.

AstraZeneca and Janssen

AstraZeneca corona vaccine and Johnson & Johnson’s Janssen vaccine do not use the MRNA technique. It is precisely these vaccines that are temporarily not used in many countries, because they are associated with blood clots in the brain and a deficiency of platelets.

According to the European Medicines Agency, the benefits of the Astrazeneca vaccine outweigh this very rare side effect. The probability of that is probably less than 1 in 100,000.

The EMA study of blood clots and platelet deficiency when using the Janssen vaccine is still ongoing. The outcome is expected next week. For the time being, according to the EEA, the benefits of this vaccine outweigh the potential risks.